# Quebec Consortium for Drug Discovery

Quebec Consortium for Drug Discovery is a Non-profit biopharmaceutical research consortium based in Montreal, Canada.

## Overview

- **Organization type:** Non-profit biopharmaceutical research consortium
- **Headquarters:** Montreal, Canada
- **Region:** North America
- **Address:** Montreal, Quebec, Canada
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** https://cqdm.org/en
- **LinkedIn:** https://www.linkedin.com/company/quebec-consortium-for-drug-discovery

## Regulatory record

- **Reports private funds:** No

## About

The Quebec Consortium for Drug Discovery was formed with provincial support from Quebec and Ontario to bridge lab research and clinical investment. It is not a single family office but a consortium that coordinates government grants, academic institutions, and private investors to de-risk drug discovery projects. The consortium funds a portfolio of small-molecule and biologic candidates, typically at preclinical through Phase I stages. Disease areas include oncology, rare genetic disorders, and metabolic conditions. It operates across Quebec and Ontario, with anchor collaborations at universities in Montreal and Toronto. Named portfolio companies include spinouts from McGill University and the Université de Montréal. Deployment and staffing figures are not public. The consortium maintains a lean operational team, supplemented by academic principal investigators and industry partners. No philanthropic foundation or separate investment vehicle has been identified as affiliated. Recent activity is not documented in public sources. The consortium represents a structural experiment in regional drug development, blending public research funding with private sector governance. Its governance model involves a board composed of academic, government, and industry representatives — distinct from typical venture capital or corporate R&D structures.

## Sectors

- Healthcare Services
- Industrial Tech
- Energy Transition & Renewables

## Offices

- Toronto, Ontario, Canada

## People

- Diane Gosselin — founder
- Véronique Dugas — operator
- Carl Baillargeon — operator

## Questions

### How does the consortium source proprietary deal flow?

Deal flow originates primarily from academic institutions in Quebec and Ontario, including McGill University and Université de Montréal. The consortium screens preclinical projects from these universities and provides funding to advance candidates toward clinical proof-of-concept. Proprietary access is driven by geographic proximity and academic partnerships.

### Which disease areas does the consortium explicitly prioritize?

The consortium targets oncology, rare genetic disorders, and metabolic conditions. It focuses on small molecules and biologics. Specific disease subareas have not been publicly detailed, but the emphasis is on unmet medical needs and assets emanating from Quebec's academic research ecosystem.

## Related profiles

- [Ghost Protocol](https://altss.com/profile/ghost-protocol)
- [Covetrus](https://altss.com/profile/covetrus)

---

Last updated: 2026-07-10T10:44:25.000Z

Canonical page: https://altss.com/profile/quebec-consortium-for-drug-discovery

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology